ABSTRACT
Rapid diagnostic tests (RDTs) that detect antigen indicative of SARS-CoV-2 infection can help in making quick health care decisions and regularly monitoring groups at risk of infection. With many RDT products entering the market, it is important to rapidly evaluate their relative performance. Comparison of clinical evaluation study results is challenged by protocol design variations and study populations. Laboratory assays were developed to quantify nucleocapsid (N) and spike (S) SARS-CoV-2 antigens. Quantification of the two antigens in nasal eluates confirmed higher abundance of N than S antigen. The median concentration of N antigen was 10 times greater than S per genome equivalent. The N antigen assay was used in combination with quantitative RT-PCR to qualify a panel composed of recombinant antigens, inactivated virus, and clinical specimen pools. This benchmarking panel was applied to evaluate the analytical performance of the SD Biosensor STANDARD Q COVID-19 Ag test, Abbott Panbio COVID-19 Ag Rapid Test, Abbott BinaxNOW COVID-19 Ag test, and the LumiraDx SARS-CoV-2 Ag Test. The four tests displayed different sensitivities toward the different panel members, but all performed best with the clinical specimen pool. The concentration for a 90% probability of detection across the four tests ranged from 21 pg/mL to 102 pg/mL of N antigen in the extracted sample. Benchmarking panels provide a quick way to verify the baseline performance of a diagnostic and enable direct comparison between diagnostic tests.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Bill & Melinda Gates Foundation (https://www.gatesfoundation.org/) via grant INV-016821. The funder did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Rapid diagnostic tests used in this work were either purchased using grant funding from the Bill & Melinda Gates Foundation, or donated by partners in support of research via grant from Abbott Laboratories and agreements from LumiraDx and the Washington State Department of Health. Donors did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
PATH's Research Determination Committee (RDC) gave ethical approval for the work with de-identified human specimens described in the manuscript.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
ABBREVIATIONS
- BEI
- BEI Resources
- BSA
- bovine serum albumin
- CDC
- US Centers for Disease Control and Prevention
- COVID-19
- coronavirus disease 2019
- Ct
- cycle threshold
- E. coli
- Escherichia coli
- EUA
- emergency use authorization
- EUL
- emergency use license
- GE
- genome equivalent
- LOD
- limit of detection
- LLOQ
- lower limit of quantification
- MSD
- Meso Scale Discovery
- N
- nucleocapsid
- NIAID
- US National Institute of Allergy and Infectious Diseases
- NIH
- US National Institutes of Health
- PBS
- phosphate-buffered saline
- qRT-PCR
- quantitative reverse transcription polymerase chain reaction
- RDT
- rapid diagnostic test
- RT-PCR
- reverse transcription polymerase chain reaction
- S
- spike
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- TCID50
- 50% tissue culture infective dose
- ULOQ
- upper limit of quantification.